ZA925B - Hyperglycemic compositions - Google Patents

Hyperglycemic compositions

Info

Publication number
ZA925B
ZA925B ZA925A ZA925A ZA925B ZA 925 B ZA925 B ZA 925B ZA 925 A ZA925 A ZA 925A ZA 925 A ZA925 A ZA 925A ZA 925 B ZA925 B ZA 925B
Authority
ZA
South Africa
Prior art keywords
hyperglycemic
compositions
hyperglycemic compositions
Prior art date
Application number
ZA925A
Other languages
English (en)
Inventor
Andrew Young
Young Andrew
Garth James Smith Cooper
James Smith Cooper Garth
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of ZA925B publication Critical patent/ZA925B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA925A 1991-01-10 1992-01-02 Hyperglycemic compositions ZA925B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/640,478 US5234906A (en) 1991-01-10 1991-01-10 Hyperglycemic compositions

Publications (1)

Publication Number Publication Date
ZA925B true ZA925B (en) 1993-03-31

Family

ID=24568421

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA925A ZA925B (en) 1991-01-10 1992-01-02 Hyperglycemic compositions

Country Status (8)

Country Link
US (1) US5234906A (xx)
EP (1) EP0525158A4 (xx)
JP (1) JPH05505626A (xx)
AU (1) AU641855B2 (xx)
CA (1) CA2076658C (xx)
SG (1) SG43866A1 (xx)
WO (1) WO1992011862A1 (xx)
ZA (1) ZA925B (xx)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2107528T3 (es) * 1991-01-10 1997-12-01 Amylin Pharmaceuticals Inc Ensayos de la actividad de la amilina.
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
ATE157010T1 (de) * 1991-05-24 1997-09-15 Amylin Pharmaceuticals Inc Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
DK0567626T3 (da) * 1991-11-19 2001-12-17 Amylin Pharmaceuticals Inc Amylin-agonist-peptider og anvendelse deraf
RU2177331C2 (ru) * 1993-09-07 2001-12-27 Амилин Фармасьютикалз, Инк. Способы регулирования моторики желудочно-кишечного тракта
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5763200A (en) * 1995-05-12 1998-06-09 Biomeasure, Incorporated Inhibition of amylin release
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5677279A (en) * 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
CN1296384C (zh) * 1999-06-18 2007-01-24 普罗特米克斯发现有限公司 具有preptin功能的肽
AU783952B2 (en) 2000-02-04 2006-01-05 Unigene Laboratories, Inc. Nasal calcitonin formulations
WO2002043566A2 (en) * 2000-11-28 2002-06-06 Baum Martin G Devices and methods for treating low blood sugar levels
US20030208113A1 (en) * 2001-07-18 2003-11-06 Mault James R Closed loop glycemic index system
US20040038861A1 (en) * 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
US20040009976A1 (en) * 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
WO2004037168A2 (en) * 2002-10-18 2004-05-06 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
WO2004060387A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20060247207A1 (en) * 2003-07-01 2006-11-02 Pierzynowski Stefan G Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1718665B1 (en) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US8404637B2 (en) 2005-02-11 2013-03-26 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
AU2006230420B2 (en) 2005-03-31 2011-11-24 Amylin Pharmaceuticals, Llc Compositions and methods for the control, prevention, and treatment of obesity and eating disorders
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US20090054305A1 (en) 2006-03-15 2009-02-26 Novo Nordisk A/S Mixtures of Amylin and Insulin
EP2010208A1 (en) 2006-03-31 2009-01-07 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
US20090181890A1 (en) * 2006-03-31 2009-07-16 Amylin Pharmaceuticals , Inc. Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
WO2007127457A2 (en) * 2006-04-28 2007-11-08 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
US20080076721A1 (en) * 2006-09-25 2008-03-27 Sal Abraham Use of branched chain fatty acid amino acid salts and compositions thereof
EP2036539A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP4159114B1 (en) 2007-10-09 2024-04-10 DexCom, Inc. Integrated insulin delivery system with continuous glucose sensor
CA2702799A1 (en) 2007-10-25 2009-04-30 Dexcom, Inc. Systems and methods for processing sensor data
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
ES2705249T3 (es) 2009-06-08 2019-03-22 Amunix Operating Inc Polipéptidos reguladores de glucosa y métodos para su producción y uso
MX2017011182A (es) 2015-03-18 2018-06-06 Zealand Pharma As Analogos de amilina.
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
CN110366424B (zh) 2016-12-27 2024-05-24 阿道恰公司 包含胰淀素、胰淀素受体激动剂或胰淀素类似物和共聚氨基酸的可注射水溶液形式的组合物
PL3658115T4 (pl) 2017-07-27 2022-08-08 Adocia Kompozycje w postaci wodnego roztworu do wstrzykiwań zawierające co najmniej insulinę ludzką a21g i co najmniej jeden supresor glukagonu o działaniu prandialnym
FR3082426A1 (fr) 2018-06-14 2019-12-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019110797A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
CN111727049A (zh) 2017-12-07 2020-09-29 阿道恰公司 Ph 7的包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的可注射溶液
FR3083086A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3083085B1 (fr) 2018-06-29 2020-10-02 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
CA3084689A1 (fr) 2017-12-07 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CN111683674A (zh) 2017-12-07 2020-09-18 阿道恰公司 包含胰淀素、胰淀素激动剂受体或胰淀素类似物和共聚氨基酸的可注射水溶液形式的组合物
WO2019115411A1 (fr) 2017-12-07 2019-06-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3084586B1 (fr) 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
US20230287040A1 (en) 2019-11-13 2023-09-14 Amunix Pharmaceuticals, Inc. Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
EP3915571A1 (en) 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
EP3915572A1 (en) 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27885A (da) * 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions

Also Published As

Publication number Publication date
SG43866A1 (en) 1997-11-14
US5234906A (en) 1993-08-10
CA2076658A1 (en) 1992-07-11
CA2076658C (en) 1996-09-03
AU1328692A (en) 1992-08-17
EP0525158A4 (en) 1993-08-25
EP0525158A1 (en) 1993-02-03
AU641855B2 (en) 1993-09-30
JPH05505626A (ja) 1993-08-19
WO1992011862A1 (en) 1992-07-23

Similar Documents

Publication Publication Date Title
EP0525158A4 (en) Hyperglycemic compositions
GB9102579D0 (en) Compositions
GB9005856D0 (en) Compositions
ZA92342B (en) Lice-repellant compositions
GB9015822D0 (en) Compositions
GB9114099D0 (en) Compositions
GB9101592D0 (en) Compositions
GB9015892D0 (en) Compositions
GB9101655D0 (en) Compositions
GB9121219D0 (en) New compositions
EP0452632A3 (en) Dichloro-pentafluoropropanes-containing compositions
GB9101654D0 (en) Compositions
GB9004832D0 (en) Compositions
HU208481B (en) Mouth-hygienicd compositions
GB9119673D0 (en) Compositions
GB9117211D0 (en) Compositions
GB9102109D0 (en) Compositions
GB9105197D0 (en) Compositions
GB9102881D0 (en) Compositions
GB9123044D0 (en) Compositions
GB9116922D0 (en) Compositions
GB9116923D0 (en) Compositions
GB9110111D0 (en) Compositions
GB9123026D0 (en) Compositions
GB9116920D0 (en) Compositions